Oncology Medications 1403 - Cigna
Oncology Medications are considered medically necessary when BOTH of the following criteria are met: a. For ONE of the below indications or uses: ... evidence, validity of the data, efficacy, and safety of the drug in specific patient populations and how well the study was designed to assess the intervention, including analysis of baseline ...
Tags:
Medication, Oncology, Efficacy, Oncology medications
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Molecular Diagnostic Testing for Hematology and Oncology ...
static.cigna.comGeneral Criteria for Somatic Mutation Genetic Testing ... initiate a related therapy and the therapy has been validated by the National Comprehensive Cancer Network™ (NCCN Guidelines™) as a category 1, 2A, or 2B recommendation for the ... Detection of circulating whole tumor cells for any other indication is considered experimental,
Bariatric Surgery and Procedures - Cigna
static.cigna.comThis Coverage Policy addresses bariatric surgery and procedures for the treatment of morbid obesity. Coverage Policy . Coverage for bariatric surgery or revision of a bariatric surgery procedure varies across plans and may be governed by state mandates. Refer to the customer’s benefit plan document for coverage details.
Anesthesia Services for Interventional Pain Management ...
static.cigna.comMonitored anesthesia care (MAC) is a service rendered by an anesthesia practitioner (i.e., anesthesiologist, certified registered nurse anesthetist CRNA]) who is not involved in the diagnostic or procedural service being performed. The ASA defines MAC as
Services, Management, Pain, Anesthesia, Interventional, Monitored, Monitored anesthesia, Anesthesia services for interventional pain management
REVENUE CODE LIST-CPT-HCPCS - Cigna
static.cigna.comREVENUE CODE LIST-CPT-HCPCS For Providers Effective March 15, 2020 . All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, includingCigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service
Minimally Invasive Spine Surgery Procedures and Trigger ...
static.cigna.comTrigger Point: Trigger point injection therapy involves the injection of anesthetic or corticosteroids into distinct, focal hyper-irritable spots (i.e., trigger points) located in a tight band of skeletal muscle. Myofascial pain syndrome is a chronic form of muscle pain centered near trigger points.
Diabetes Equipment and Supplies
static.cigna.com• hypoglycemic wristband alarm (e.g., Diabetes Sentry™) External Insulin Pumps . ANY of the following external insulin pumps * is considered medically necessary for the management of type 1 and type 2 diabetes mellitus: • an external insulin pump* (HCPCS code E0784) including a combined or integrated continuous
Welcome to Cigna Behavioral Health
static.cigna.comThe practitioner has thirty (30) days from the receipt of the suspension or termination letter to make a written request for reconsideration. Cigna Behavioral Health's Credentialing Committee Appeal Panel will review the appeal at its next monthly meeting and issue a written notification of the outcome to the practitioner.
Speech Therapy - Cigna
static.cigna.comspeech-language pathologist for a significant voice disorder associated with the laryngeal structures that are associated with anatomic abnormality, neurological condition, injury (e.g., vocal nodules or polyps, vocal cord paresis or paralysis, paradoxical vocal …
Nucleic Acid Pathogen Testing - Cigna
static.cigna.como human papillomavirus (HPV) cervical cancer screening • Symptomatic individuals when the associated signs and symptoms or diagnoses, are listed in the ... Chlamydial infection is the most frequently reported infectious disease in the United States (IDSA, 2018; CDC,
Pathogens, Testing, Human, Acid, Infections, Cervical, Nucleic, Papillomavirus, Human papillomavirus, Nucleic acid pathogen testing
Transcranial Magnetic Stimulation
static.cigna.comTranscranial Magnetic Stimulation (TMS) for Depression . Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique that modulates cortical excitability. In repetitive TMS (rTMS), trains of several pulses are delivered through repeated stimulation over the same area with frequencies ranging from 1 to 20 Hz.
Related documents
Efficacy endpoints in Oncology
www.lexjansen.comEfficacy endpoints in Oncology Angelo Tinazzi, Cytel Inc., Geneva, Switzerland ABSTRACT The evaluation of efficacy in oncology studies, in particular for solid tumors, is pretty standard and well defined by several regulatory guidance (e.g. EMA and FDA), including some specific cancer type guidance (e.g. NSCLC from FDA).
Oncology, Efficacy, Endpoint, Efficacy endpoints in oncology, Efficacy in oncology
Molecular Oncology Testing for Cancer Diagnosis, Prognosis ...
www.uhcprovider.comMolecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions Page 1 of 57 ... and not medically necessary due to insufficient evidence of efficacy. Note: This does not apply to BCI testing. Gene Expression Tests for breast cancer are unproven and not medically necessary for all other indications, including
Treatment, Decision, Diagnosis, Oncology, Cancer, Prognosis, Efficacy, Cancer diagnosis, And treatment decisions
NCCN Clinical Practice Guidelines in Oncology (NCCN ...
www2.tri-kobe.orgNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ... Efficacy was noted in Stage IIIB, IIIC, and Stage IV-M1a disease and was more likely in patients who were treatment naive." ME-8 • Treatment of Local, Satellite, and/or In-transit Recurrence:
Clinical Development Success Rates and Contributing ...
pharmaintelligence.informa.comOncology: largest segment of industry, modest success rates 27 ... and is not dependent on efficacy for candidates to advance, it is common for this phase to have a higher success rate among the clinical phases across most categories analyzed in this report. However, Phase I
Development, Clinical, Rates, Success, Oncology, Efficacy, Clinical development success rates
NCCN Clinical Practice Guidelines in Oncology (NCCN ...
www2.tri-kobe.orgThere are limited data on the efficacy of bevacizumab in the recurrence therapy setting for patients previously treated with bevacizumab. • Footnote "m" added: "If response after chemotherapy, bevacizumab can be continued as maintenance therapy until disease progression or unacceptable toxicity." OV-6
Investor science conference call: American Society of ...
www.astrazeneca.comJan 24, 2021 · Oncology Research and Development Speakers 3 Dr Bruno Sangro Investigator, HIMALAYA and Professor –Head Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra Susan Galbraith Dr Arndt Vogel Steering Committee member, TOPAZ-1 and Professor - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School